CN100345868C - Dermatan sulfate with low molecule and its preparing method - Google Patents
Dermatan sulfate with low molecule and its preparing method Download PDFInfo
- Publication number
- CN100345868C CN100345868C CNB031121802A CN03112180A CN100345868C CN 100345868 C CN100345868 C CN 100345868C CN B031121802 A CNB031121802 A CN B031121802A CN 03112180 A CN03112180 A CN 03112180A CN 100345868 C CN100345868 C CN 100345868C
- Authority
- CN
- China
- Prior art keywords
- dermatan sulfate
- molecular weight
- low molecular
- sulfate
- weight dermatan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to low molecular dermatan sulfate and a preparation method thereof, which belongs to the field of biologic medicine. The low molecular dermatan sulfate is obtained by degrading dermatan sulfate, and the molecular weight is from 3000 to 8000 daltons. In the preparation method, dermatan sulfate is degraded with hydrogen peroxide under mild conditions, and the low molecular dermatan sulfate is obtained after the processes of ultrafiltration and gel chromatography through separation and purification. The low molecular dermatan sulfate prepared in the present invention has strong action on thrombus resistance and certain action on thrombolysis, and also has the advantages of easy absorption for oral taking, long half life, high bioavailability, etc.
Description
Technical field
The invention belongs to biomedicine field, particularly relate to a kind of low molecular weight dermatan sulfate and preparation method thereof.
Background technology
Dermatan sulfate is a class formation complexity, Sulfated glycosaminoglycan, and the natural product molecular weight extensively is present in the animal tissues generally at 15kD～45kD.Studies show that both at home and abroad the dermatan sulfate anticoagulating active is lower than unfraction heparin, its antithrombotic acitivity is but obviously than unfraction heparin height, and hemorrhage side effect is obviously little than unfraction heparin, so dermatan sulfate has become a kind of novel antithrombotic reagent.Yet there are two main pharmacokinetics problems in dermatan sulfate: one is that the transformation period is shorter, and another is subcutaneous and during the intramuscular injection path administration, and bioavailability is low.Along with the rising of dermatan sulfate molecular weight, its bioavailability reduces.People such as Mascellani had once reported a kind of preparation method of low molecular weight dermatan sulfate at United States Patent (USP) " dermatan sulfate and pharmaceutical preparation composition thereof with degraded of anti-thrombosis function, fibrinolysis and anti-inflammatory activity " (patent No. US4973580), this method is to make the catalyst degradation dermatan sulfate with heavy metal ion, have complex process, yield is low, and has introduced harmful shortcomings such as heavy metal ion.
Summary of the invention
The objective of the invention is to overcome above-mentioned the deficiencies in the prior art, single use the hydrogen peroxide degradation dermatan sulfate, a kind of low molecular weight dermatan sulfate with stronger anti thrombotic action and certain thrombolytic effect and preparation method thereof is provided.
The present invention realizes by following approach:
A kind of low molecular weight dermatan sulfate; a kind of low molecular weight dermatan sulfate; contain iduronic acid derivative and acetylamino galactosamine derivative in the molecular structure; it is characterized in that: molecular structure is made up of 2-O-sulfate-iduronic acid-(1 → 3)-2-N-ethanoyl-2-deoxidation-4-O-sulfate semi-lactosi; also contain 2-N-ethanoyl-2-deoxidation-4 in the sugar chain; 6-O-two sulfate semi-lactosis, its chemical structure is as follows:
Above-mentioned low molecular weight dermatan sulfate is characterized in that: molecular weight is 3000～8000 dalton, and the ratio of sulfate radical and carboxylate radical is 0.8～1.2, and activating heparin cofactor II activity is 100～200U/mg, anticoagulant efficiency≤10IU/mg.
The hydrogen peroxide degradation method that the present invention sets up causes the fracture of dermatan sulfate main chain (1 → 4) glycosidic link, obtain low molecular weight dermatan sulfate, do not introduce other impurity, improve temperature of reaction and increase the molecular weight that concentration of hydrogen peroxide helps reducing dermatan sulfate, controlling reaction time can obtain the product of desired molecule amount.
A kind of method for preparing above-mentioned low molecular weight dermatan sulfate is characterized in that may further comprise the steps:
(1) degraded of dermatan sulfate: the concentration of the dermatan sulfate aqueous solution is 1%～10%, the pH value of solution is 4～10, the concentration of hydrogen peroxide is 1%～20%, temperature is 20～80 ℃, reaction times is 2～18 hours, degraded finishes and uses organic solvent deposit, organic solvent commonly used such as methyl alcohol, ethanol, acetone, Virahol etc.;
(2) separate needed low molecular weight dermatan sulfate fragment: after above-mentioned degraded product is made into the aqueous solution, separate needed fragment with gel chromatography with ultrafiltration process, gel commonly used is Sephadex G-50, Sephadex G-75, Sephadex G-100, Superdex 200 etc., carry out wash-out with sodium chloride solution, the concentration of sodium-chlor is 0.01～1.0mol/L.Collect the high part of low molecular weight dermatan sulfate content, with Sephadex G-10 desalination, the lyophilize sub-dermatan sulfate that makes low score.
The low molecular weight dermatan sulfate that the present invention makes has stronger anti thrombotic action and certain thrombolytic effect, also has oral easy absorption, long half time and bioavailability advantages of higher.
Embodiment
Provide a preferred examples of the invention process below.
The key of low molecular weight dermatan sulfate preparation is the control molecular weight, and this method adopts the hydrogen peroxide degradation method, obtains the controllable low molecular weight dermatan sulfate of palliating degradation degree.
(1) preparation of low molecular weight dermatan sulfate: dermatan sulfate elaboration 1g is made into 1.0% solution with distilled water, regulate pH4～5, drip 30% hydrogen peroxide and make final concentration reach 2%, in 70 ℃ of stirring in water bath 15 hours, transfer pH7 with sodium hydroxide solution, 3 times of amount methanol extractions;
(2) purifying of low molecular weight dermatan sulfate: the throw out of step (1) is made into 0.5% solution, with the molecular retention value is the membrane ultrafiltration of 8kD, collect and see through liquid, after concentrating with Rotary Evaporators, and last Sephadex G-100 preparative chromatography post (2.6 * 82cm), with 0.3mol/L sodium chloride solution wash-out, the 206nm ultraviolet detection, collect the high part of low molecular weight dermatan sulfate content, with Sephadex G-10 desalination, lyophilize gets required low molecular weight dermatan sulfate.
The low molecular weight dermatan sulfate of above-mentioned gained is carried out molecular weight determination, structure determination and anticoagulant efficiency respectively to be measured and obtains a kind of low molecular weight dermatan sulfate; contain iduronic acid derivative and acetylamino galactosamine derivative in the molecular structure; molecular structure is made up of 2-O-sulfate-iduronic acid-(1 → 3)-2-N-ethanoyl-2-deoxidation-4-O-sulfate semi-lactosi; also contain 2-N-ethanoyl-2-deoxidation-4 in the sugar chain; 6-O-two sulfate semi-lactosis, its chemical structure is as follows:
The relative molecular weight of this low molecular weight dermatan sulfate is 3000～8000 dalton, and the ratio of sulfate radical and carboxylate radical is 0.8～1.2, and activating heparin cofactor II activity is 100～200U/mg, anticoagulant efficiency≤10IU/mg.
Claims (2)
1. low molecular weight dermatan sulfate; contain iduronic acid derivative and acetylamino galactosamine derivative in the molecular structure; molecular structure is made up of 2-O-sulfate-iduronic acid-(1 → 3)-2-N-ethanoyl-2-deoxidation-4-O-sulfate semi-lactosi; also contain 2-N-ethanoyl-2-deoxidation-4 in the sugar chain; 6-O-two sulfate semi-lactosis and 2-O-sulfate glucuronic acid, its chemical structure is as shown below:
N=2-22 wherein, X=SO
3Or H, Y=H or SO
3
It is characterized in that: range of molecular weight distributions is 3000～8000 dalton, and the ratio of sulfate radical and carboxylate radical is 0.8～1.2, and activating heparin cofactor II activity is 100～200U/mg, anticoagulant efficiency≤10IU/mg.
2. method for preparing the described low molecular weight dermatan sulfate of claim 1 is characterized in that may further comprise the steps:
(1) preparation of low molecular weight dermatan sulfate: the dermatan sulfate elaboration is made into 1.0%～10% solution with distilled water, regulate pH4～10, the hydrogen peroxide of dropping 30% makes final concentration reach 1%～20%, in temperature is 20～70 ℃ of stirring in water bath 2～18 hours, transfer pH7 with sodium hydroxide solution, 3 times of amount methanol extractions;
(2) purifying of low molecular weight dermatan sulfate: the throw out of step (1) is made into 0.5% solution, with the molecular retention value is the membrane ultrafiltration of 8kD, collect and see through liquid, after concentrating with Rotary Evaporators, last SephadexG-75 preparative chromatography post with 0.01～1.0mol/L sodium chloride solution wash-out, is collected the high part of low molecular weight dermatan sulfate content, with Sephadex G-10 desalination, lyophilize gets required low molecular weight dermatan sulfate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031121802A CN100345868C (en) | 2003-04-18 | 2003-04-18 | Dermatan sulfate with low molecule and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031121802A CN100345868C (en) | 2003-04-18 | 2003-04-18 | Dermatan sulfate with low molecule and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1445245A CN1445245A (en) | 2003-10-01 |
| CN100345868C true CN100345868C (en) | 2007-10-31 |
Family
ID=27814614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031121802A Expired - Fee Related CN100345868C (en) | 2003-04-18 | 2003-04-18 | Dermatan sulfate with low molecule and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100345868C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101168570B (en) * | 2007-11-15 | 2010-05-26 | 暨南大学 | Method for degrading kelp polysaccharide sulfate |
| CN106146688A (en) * | 2016-07-27 | 2016-11-23 | 河北常山生化药业股份有限公司 | Heparinoid technique prepared by heparin sodium leftover bits and pieces |
| CN106188341B (en) * | 2016-07-27 | 2019-09-17 | 河北常山生化药业股份有限公司 | Heparin sodium leftover bits and pieces prepares high-purity sulfuric acid dermatan technique |
| CN111040047A (en) * | 2019-12-11 | 2020-04-21 | 东营天东制药有限公司 | Process and application for refining low-molecular dermatan sulfate by enzyme-ultrafiltration method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1259143A (en) * | 1997-06-03 | 2000-07-05 | 里奥药物制品有限公司 | Oligosaccharide mixtures having antithrombotic activity |
-
2003
- 2003-04-18 CN CNB031121802A patent/CN100345868C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1259143A (en) * | 1997-06-03 | 2000-07-05 | 里奥药物制品有限公司 | Oligosaccharide mixtures having antithrombotic activity |
Non-Patent Citations (2)
| Title |
|---|
| 硫酸皮肤素寡糖的分离与制备 于广利 等，青岛海洋大学学报，第31卷第6期 2001 * |
| 硫酸皮肤素的研究概况 石滨 等，中国生化药物杂志，第22卷第2期 2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1445245A (en) | 2003-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0347588B1 (en) | Heparin derivatives and process for their preparation | |
| US8193166B2 (en) | Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation | |
| US11155569B2 (en) | Method of degrading polysaccharide using ozone | |
| NO300277B1 (en) | Process for the preparation of a mixture containing N, O-sulfated heparosan | |
| CN101544999A (en) | Method for producing and purifying high purity and low molecular weight sodium heparin | |
| CN1244702C (en) | Method of producing heparin oligosaccharide using heparinase | |
| CN1267457C (en) | Method for preparing low molecular weight seaweed polysaccharide sulfate | |
| CN1284800C (en) | Highly sulfacted derivatives of K5 polysaccharide and their preparation | |
| CN100345868C (en) | Dermatan sulfate with low molecule and its preparing method | |
| CN106146682B (en) | A method of the large molecular weight polysaccharides of the degradation glycosidic bonds of -1,3- containing α | |
| CA1195322A (en) | Process for manufacturing low molecular weight heparins by depolymerization of normal heparin | |
| CN114350728A (en) | Method for preparing hyaluronic acid oligosaccharide by enzyme method | |
| CN106188327B (en) | A method of the large molecular weight polysaccharides of the degradation glycosidic bonds of -1,4- containing β | |
| CN1789287A (en) | Poly-sulfated chondroitin sulfate and preparation method thereof | |
| EP1694714B1 (en) | Low molecular weight polysaccharides having antithrombotic activity | |
| CN113603732B (en) | Non-animal chondroitin sulfate oligosaccharide and preparation method thereof | |
| CN1803853A (en) | Low molecular weight heparin sodium and affinity chromatography preparation method thereof | |
| CN1317287C (en) | Oligose polysulfate and preparation process thereof | |
| CN114410708B (en) | Method for improving in-vitro antioxidant activity and biological flocculation of nostoc flagelliforme extracellular polysaccharide | |
| CN115448994B (en) | Low molecular weight heparin capable of neutralizing anticoagulation, preparation method and application thereof | |
| CN106084085A (en) | A kind of preparation method and application of low-molecular-weight algal polysaccharide sulfate | |
| RU2333222C2 (en) | Epimerised k5 polysaccharide derivatives with high sulfation degree | |
| US20120253029A1 (en) | Process for the preparation of highly o-sulfated epimerized derivatives of k5 polysaccharide and intermediates therein | |
| CN105504088B (en) | A kind of long-acting low toxicity and the iron chelator with oxidation response | |
| JPH11106404A (en) | New polysaccharide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071031 Termination date: 20100418 |